Ecopetrol
EC
Petroleo Brasileiro SA Petrobras
PBR
Taylor Morrison Home
TMHC
KB Home
KBH
Meritage Homes
MTH
US Stock MarketDetailed Quotes
PRLD Prelude Therapeutics
- 1.200
- -0.140-10.45%
Trading Dec 30 13:14 ET
66.04MMarket Cap-0.68P/E (TTM)
1.378High1.200Low196.53KVolume1.330Open1.340Pre Close240.66KTurnover1.41%Turnover RatioLossP/E (Static)55.04MShares6.80052wk High0.42P/B16.69MFloat Cap0.79752wk Low--Dividend TTM13.91MShs Float95.375Historical High--Div YieldTTM13.28%Amplitude0.797Historical Low1.224Avg Price1Lot Size
About Prelude Therapeutics Company
Prelude Therapeutics, Inc. is a clinical-stage oncology company, which engages in the development of novel precision cancer medicines. It also focuses on the design and development of small molecule agents for cancer medicines. The company was founded by Krishna Vaddi in 2016 and is headquartered in Wilmington, DE.
Company Profile
SymbolPRLD
Company NamePrelude Therapeutics
Listing DateSep 25, 2020
Issue Price19.00
Founded2016
CEODr. Krishna Vaddi, PhD
MarketNASDAQ
Employees128
Fiscal Year Ends12-31
Address175 Innovation Boulevard
CityWilmington
ProvinceDelaware
CountryUnited States of America
Zip Code19805
Phone1-302-467-1280
Websitehttp://www.preludetx.com
Company Executives
- Name
- Position
- Salary
- Dr. Krishna Vaddi, PhD
- Director and Chief Executive Officer
- 2.64M
- Bryant D. Lim
- Interim Chief Financial Officer, Chief Legal Officer and Corporate Secretary
- 1.61M
- Peggy A. Scherle, PhD
- Chief Scientific Officer
- --
- Dr. Jane Huang, M.D.
- President and Chief Medical Officer
- 1.65M
- Andrew P. Combs, PhD
- Chief Chemistry Officer
- --
- Dr. Paul A. Friedman,M.D.
- Chairman of the Board
- 161.03K
- Mardi C. Dier
- Independent Director
- 147.03K
- Julian C. Baker
- Independent Director
- 140.03K
- Martin Babler
- Independent Director
- 134.53K
- Dr. David P. Bonita, M.D.
- Independent Director
- 144.53K
- Dr. Victor Sandor, C.M.,M.D.
- Independent Director
- 131.03K
Trending US Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.